Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.72 USD | -8.53% | -11.63% | -25.48% |
09/05 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
09/05 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.48% | 219.19Cr | |
+54.05% | 5.87TCr | |
-2.02% | 4.13TCr | |
+40.01% | 3.92TCr | |
-10.22% | 2.74TCr | |
+13.42% | 2.65TCr | |
-21.60% | 1.9TCr | |
+2.89% | 1.25TCr | |
+22.40% | 1.19TCr | |
+27.49% | 1.21TCr |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Morgan Stanley Adjusts Price Target on Intellia Therapeutics to $86 From $83, Maintains Overweight Rating